<< FEMA grant for designing next generation firefighter gloves | Presentations on seasonal influenza and H1N1 viruses >>

ACCC approves Pfizer's pending acquisition of Wyeth

Published on September 30, 2009 at 5:09 AM · No Comments

Pfizer Inc (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Wyeth. The ACCC’s decision includes Pfizer’s commitment to divest certain animal health assets in Australia.

“We are pleased to have achieved another significant milestone this week with the ACCC’s approval of the pending acquisition,” said Jeff Kindler, chairman and chief executive officer, Pfizer. The transaction remains subject to regulatory approval in the United States and Canada. Pfizer expects to obtain these approvals shortly and to close the transaction early in the fourth quarter 2009.

Source: Pfizer Inc.

08286c44-597c-40bf-adde-86328482646f|0|.0

Posted in:

Tags: Pfizer

Celldex reports net loss of $6.6 million for first-quarter 2010Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 20...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.